King's CollegeAllergyEpsilogen Ltd completes £12.5m Series B expansionA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept … more ➔
Hayo Therapeutics SAObesitySwiss RNA maker Haya in huge licence dealSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions. more ➔
Innerstream - wikimedia.orgMultiple sclerosisRoche with good interim clinical resultsRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis more ➔
Individor plcPartnershipIndividor set to waive AEF0117 licence after Phase IIb failureFollowing the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise … more ➔
Nxtera Pharma LtdDealNxera Pharma Ltd collects clinical US$35m milestoneNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568. more ➔
marquetand - pixapay.comDrug developmentResearchers present AI-guided protein design toolDanish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many … more ➔
Amiferia ABVetmedAmferia partners with Biokema expanding into SwitzerlandSwedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology … more ➔
Veronika SaninScreeningConfusion in Germany about useful genetic testingThe extent to which vested interests can delay innovation can currently be seen in the introduction of screening for the dominantly inherited disease familial hypercholesterolaemia, the benefits of which … more ➔
pixabay.com/SD-PicturesAIAI identifies most effective climate policiesA brand-new AI analysis of 1,500 climate policies across 41 countries between 1998 and 2022 reveals that only 4% achieved significant emission reductions. more ➔
Biopôle SAFinancingVandria closes Series A round at CHF28.3mSwiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing. more ➔
King's College
Hayo Therapeutics SA
Innerstream - wikimedia.org
Individor plc
Nxtera Pharma Ltd
marquetand - pixapay.com
Amiferia AB
Veronika Sanin
pixabay.com/SD-Pictures
Biopôle SA